Got $300? 2 Biotech Stocks to Buy and Hold Forever

2026-02-16 06:08:00 ET

Krystal Biotech (NASDAQ: KRYS) and ARS Pharmaceuticals (NASDAQ: SPRY) have been gaining a lot of attention over the past year, thanks to the potential in their groundbreaking -- and for now, only -- commercial therapies.

In 2023, Krystal pioneered Vyjuvek, the first topical genetic therapy and first treatment approved by the Food and Drug Administration (FDA) for dystrophic epidermolysis bullosa, a rare skin disorder. In 2024, ARS Pharma got FDA approval for Neffy, a nasal spray that's the first epinephrine product for the treatment of anaphylaxis that is not administered by injection.

Both biotechs are working to expand the labels for their lead therapies while using their growing revenues to fund their pipelines. Like any biotech with only one commercialized treatment, each stock presents significant risks, but has considerable upside potential as well.

Continue reading